Which laboratory panels should be ordered for a patient with elevated liver enzymes and a history of alcohol use?

Laboratory Evaluation for Elevated Liver Enzymes with Alcohol Use History

Order a core liver aetiology panel immediately, including hepatitis B surface antigen, hepatitis C antibody, autoimmune markers (ANA, ASMA, immunoglobulins), iron studies (ferritin and transferrin saturation), and lipid profile, while simultaneously obtaining alcohol-specific biomarkers such as carbohydrate-deficient transferrin (CDT) to confirm ongoing heavy drinking. 1

Initial Core Laboratory Panel

The standard liver aetiology screen should include 1:

• Hepatitis B surface antigen (HBsAg) - to exclude viral hepatitis B 1
• Hepatitis C antibody - followed by PCR if positive 1
• Autoimmune markers: antinuclear antibody (ANA), anti-smooth muscle antibody (ASMA), and immunoglobulin G levels - to exclude autoimmune hepatitis 1
• Iron studies: serum ferritin and transferrin saturation - to assess for hemochromatosis (transferrin saturation >45% is significant) 1
• Anti-mitochondrial antibody (AMA) - if cholestatic pattern present, to exclude primary biliary cholangitis 1
• Lipid profile and fasting glucose - to assess for metabolic syndrome and NAFLD 1

Alcohol-Specific Biomarkers

For patients with suspected alcohol use, add 1, 2:

• Carbohydrate-deficient transferrin (%CDT) - highest diagnostic performance (AUC 0.77) for detecting excessive drinking, requires 50-80g ethanol daily for 1-2 weeks to become positive 1, 2
• Gamma-glutamyl transferase (GGT) - second-best marker (AUC 0.68), though elevated in many liver conditions 1, 2
• Mean corpuscular volume (MCV) - elevated with chronic alcohol use 1, 2
• AST/ALT ratio - calculate this from standard liver enzymes already obtained 2, 3

Pattern Recognition for Alcohol-Related Liver Disease

The biochemical signature of alcoholic liver disease includes 2, 4, 3:

• AST/ALT ratio >2 - highly suggestive of alcoholic cirrhosis (present in 51% of cirrhotic patients but only 2% of excessive drinkers without cirrhosis) 2
• AST rarely exceeds 300 U/L in ALD 1
• GGT elevation - typically higher in ALD than other liver diseases, though loses specificity in advanced fibrosis 1
• Isolated elevated ferritin - commonly reflects dysmetabolic iron overload from alcohol/NAFLD, not hemochromatosis 1

Extended Panel Considerations

Reserve extended testing for patients without clear diagnosis from core panel 1:

• Hepatitis A and E serology - if ALT >1000 U/L 1
• Cytomegalovirus serology - if ALT >1000 U/L 1
• Ceruloplasmin - if age <40 years or neuropsychiatric symptoms 1
• Alpha-1 antitrypsin level - if family history or early-onset disease 1

Critical Clinical Context Required

Obtain specific history details 1, 5:

• Quantified alcohol intake: current and past consumption in grams/day or standard drinks/week, use AUDIT-C screening 1, 5
• Duration of drinking: CDT requires 1-2 weeks of heavy use (50-80g/day) to become positive 1
• Metabolic risk factors: BMI, diabetes, hypertension, dyslipidemia - to assess for concurrent NAFLD 1
• Medication history: prescribed, over-the-counter, herbal supplements 1
• Risk factors for viral hepatitis: country of birth, injection drug use, transfusions 1

Important Caveats

• Do not simply repeat liver enzymes - 84% remain abnormal at 1 month and 75% at 2 years, so investigate the cause rather than recheck 1
• CDT has limitations: false negatives occur in cirrhosis, and various confounding factors affect results 1
• AST/ALT ratio <1 suggests non-alcoholic liver disease (NASH or viral hepatitis) rather than ALD 3
• Focused testing is more cost-effective when pre-test probability is high based on clinical assessment 6
• Immediate referral indicated for jaundice or suspected malignancy 1

Monitoring During Abstinence

If alcohol cessation is achieved, expect 2:

• CDT normalizes in 2-3 weeks, with 43% reduction by 12 weeks 1, 2
• GGT decreases by 19% at 12 weeks 2
• MCV decreases by 2.7% at 12 weeks 2
• AST/ALT ratio remains unchanged during early abstinence 2